GSK plc
Search results
1 day ago · H1 and Q2 2024 results. PUBLISHED 25 July 2024. Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Building on our strong growth in the first half of the year and continued underlying demand for our medicines we are upgrading our FY 2024 guidance for both Total Revenue and Core EPS. At our Investor Day in ...
- Careers
At AstraZeneca, Data Science has the potential to transform...
- Contact Us
If you have questions about a specific medical condition,...
- Medicines
In some cases, health care professionals and patients can...
- Our Company
At AstraZeneca, sustainability is part of our DNA, embedded...
- Pipeline
Pipeline - H1 and Q2 2024 results - astrazeneca.com
- Press Releases
Press Releases - H1 and Q2 2024 results - astrazeneca.com
- Cardiovascular, Renal and Metabolism (CVRM) | AstraZeneca
- Respiratory and Immunology - Our therapy areas - AstraZeneca
- Great place to work – Our company - AstraZeneca
- Articles - AstraZeneca
- Precision medicine for chronic diseases
- Data Science & Artificial Intelligence: Unlocking new science insights
- Our technologies
- Careers
12 hours ago · Sales in AstraZeneca's top business, oncology, grew 19% at constant currency rates to $5.33 billion and accounted for 41% of the total, while its rare disease and heart and kidney disease ...
1 day ago · AstraZeneca has raised its sales and profit outlook for the year on the back of strong sales of its cancer medicines, as the UK’s largest company nears a £200bn valuation. Sales of its drugs ...
1 day ago · AstraZeneca reported earnings per share of $4.03, a year-over-year increase of 5%. In this way, Soriot said, the company is able to better "manage the turbulences" of the geopolitical landscape.
- 9 min
- Anjalee Khemlani
1 day ago · AstraZeneca Plc raised its profit and sales forecast for the year as it was boosted by demand for blockbuster cancer drugs. Earnings per share, excluding some items, are now expected to rise by a ...
1 day ago · AstraZeneca increased the interim dividend by 7 US cents to $1 (77.6 pence, 10.79 SEK). It also upgraded the guidance for the fiscal year 2024, expecting total revenue and core earnings per share ...
19 hours ago · CAMBRIDGE, Britain — CAMBRIDGE, Britain — Astrazeneca PLC (AZN) on Thursday reported second-quarter net income of $1.93 billion. On a per-share basis, the Cambridge, Britain-based company said ...
